GB9023352D0 - Vaccinia vectors,vaccinia genes and expression products thereof - Google Patents

Vaccinia vectors,vaccinia genes and expression products thereof

Info

Publication number
GB9023352D0
GB9023352D0 GB909023352A GB9023352A GB9023352D0 GB 9023352 D0 GB9023352 D0 GB 9023352D0 GB 909023352 A GB909023352 A GB 909023352A GB 9023352 A GB9023352 A GB 9023352A GB 9023352 D0 GB9023352 D0 GB 9023352D0
Authority
GB
United Kingdom
Prior art keywords
vaccinia
expression products
genes
vectors
vaccinia vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB909023352A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lynxvale Ltd
Original Assignee
Lynxvale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lynxvale Ltd filed Critical Lynxvale Ltd
Priority to GB909023352A priority Critical patent/GB9023352D0/en
Publication of GB9023352D0 publication Critical patent/GB9023352D0/en
Priority to EP91918806A priority patent/EP0555291A1/en
Priority to CA002094821A priority patent/CA2094821A1/en
Priority to JP3517131A priority patent/JPH06502069A/en
Priority to PCT/GB1991/001882 priority patent/WO1992007944A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24161—Methods of inactivation or attenuation
GB909023352A 1990-10-26 1990-10-26 Vaccinia vectors,vaccinia genes and expression products thereof Pending GB9023352D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB909023352A GB9023352D0 (en) 1990-10-26 1990-10-26 Vaccinia vectors,vaccinia genes and expression products thereof
EP91918806A EP0555291A1 (en) 1990-10-26 1991-10-28 Vaccinia vectors, vaccinia genes and expression products thereof
CA002094821A CA2094821A1 (en) 1990-10-26 1991-10-28 Vaccinia vectors, vaccinia genes and expression products thereof
JP3517131A JPH06502069A (en) 1990-10-26 1991-10-28 Vaccinia vector, vaccinia gene and its expression product
PCT/GB1991/001882 WO1992007944A1 (en) 1990-10-26 1991-10-28 Vaccinia vectors, vaccinia genes and expression products thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909023352A GB9023352D0 (en) 1990-10-26 1990-10-26 Vaccinia vectors,vaccinia genes and expression products thereof

Publications (1)

Publication Number Publication Date
GB9023352D0 true GB9023352D0 (en) 1990-12-05

Family

ID=10684414

Family Applications (1)

Application Number Title Priority Date Filing Date
GB909023352A Pending GB9023352D0 (en) 1990-10-26 1990-10-26 Vaccinia vectors,vaccinia genes and expression products thereof

Country Status (5)

Country Link
EP (1) EP0555291A1 (en)
JP (1) JPH06502069A (en)
CA (1) CA2094821A1 (en)
GB (1) GB9023352D0 (en)
WO (1) WO1992007944A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204780D0 (en) * 1992-03-05 1992-04-15 Smith Geoffrey L Vaccinia vectors,vaccinia genes,and expression products thereof;pharmaceuticals,reagents and methods
DK0758397T3 (en) * 1994-04-29 2005-10-10 Baxter Healthcare Sa Recombinant poxviruses with foreign polynucleotides in essential regions
US7285526B2 (en) 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (en) 2004-12-15 2007-02-28 Neuralab Ltd AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION
EA037929B1 (en) 2005-03-23 2021-06-08 Генмаб А/С Antibodies against human cd38 and use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (en) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
NZ608143A (en) * 2010-10-15 2015-02-27 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) influenza vaccine
WO2014172309A2 (en) * 2013-04-18 2014-10-23 The United States Of America As Represented By The Secretary Of The Army, On Behalf Of The United Therapeutic compositions for neutralizing type i interferons, and methods of use

Also Published As

Publication number Publication date
CA2094821A1 (en) 1992-04-27
WO1992007944A1 (en) 1992-05-14
JPH06502069A (en) 1994-03-10
EP0555291A1 (en) 1993-08-18

Similar Documents

Publication Publication Date Title
AP9100317A0 (en) Oligomers,their uses and formulations
PH30902A (en) Improved hair conditioning shampoo.
HU9202956D0 (en) Hair styling shampoos
EP0440494A3 (en) Hair dyeing
ZA919797B (en) Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
IL99496A0 (en) Onco-fetal gene,its protein product and their uses
AP9600796A0 (en) Novel insecticidal 2,4 diaminoquina-zolines
GB9012150D0 (en) Hair products applier
GB9023352D0 (en) Vaccinia vectors,vaccinia genes and expression products thereof
HUT64206A (en) Gentle shampoos
GB8907468D0 (en) Vaccinia vectors,vaccinia genes and expression products thereof
AU9066191A (en) Counterpressure garment
ZA921321B (en) Improved yeast vectors
HU9204180D0 (en) /3.3-c/pyrazole-steroides and /3,2-d/triazole ones of antiandrogenic effect
EP0481950A3 (en) 1,4-dideoxy-4-fluoronojirimycin
ZA933848B (en) Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxides
GB9204780D0 (en) Vaccinia vectors,vaccinia genes,and expression products thereof;pharmaceuticals,reagents and methods
EP0437516A4 (en) H. saimiri-htlv-x region vector
GB8909855D0 (en) Expression vector
GB9027606D0 (en) Genes expression
GB9009537D0 (en) Expression vector
IE883270L (en) Dna expression vectors
CS263290A2 (en) Hair chignon
IE893219L (en) H.saimiri-htlv-x region vector
CA71287S (en) Hair care item